» Articles » PMID: 6714269

The Metabolic Fate of 2H-labelled Propafenone in Man

Overview
Date 1984 Jan 1
PMID 6714269
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The metabolism of propafenone was studied in three humans by using 300 mg of the deuterated compound given orally. The excretion of propafenone and its metabolites was assessed by measuring the deuterium content in the excretion products by means of a microwave plasma detector. At selected times the metabolic pattern in plasma, urine, bile and feces was determined. The metabolites were isolated and the structure of the main compounds was characterized. Propafenone is absorbed completely and quantitatively metabolized. Unchanged propafenone is excreted neither in the urine nor in the feces in amounts of more than 1% the dose. The percentage of free unconjugated propafenone of the total deuterium content in the plasma was about 10% 3 and 6 hours after application. Conjugates of hydroxylated derivatives of propafenone are present predominantly in the plasma. The excretion of the metabolites takes place mainly by way of the feces, 53% of the dose is excreted by this route within 48 hours. Urinary elimination accounted for 18.5 and 38% of the dose within 48 hours in two humans. It was possible to elucidate the structure of 11 metabolites, accounting for more than 90% of the dose administered. The major metabolites are conjugates of 5-hydroxypropafenone and hydroxy-methoxy-propafenone with glucuronic and sulphuric acid and propafenone glucuronide. Furthermore, metabolic products of oxydative deamination pathway were identified, i.e. a glycol and a lactic acid derivative. C-C splitting yields a relatively large amount of 3-phenyl-propionic acid, while cleavage of the ether group leads to a phenolic product and is only of minor importance.

Citing Articles

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou S Clin Pharmacokinet. 2009; 48(11):689-723.

PMID: 19817501 DOI: 10.2165/11318030-000000000-00000.


Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.

Reder-Hilz B, Ullrich M, Ringel M, Hewitt N, Utesch D, Oesch F Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(4):408-17.

PMID: 14999438 DOI: 10.1007/s00210-004-0875-z.


New antiarrhythmic drugs in pediatric use: propafenone.

Paul T, Janousek J Pediatr Cardiol. 1994; 15(4):190-7.

PMID: 7991437 DOI: 10.1007/BF00800674.


Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Capucci A, Boriani G Drug Saf. 1995; 12(1):55-72.

PMID: 7741984 DOI: 10.2165/00002018-199512010-00005.


Drug interaction between propafenone and metoprolol.

Wagner F, Kalusche D, Trenk D, Jahnchen E, ROSKAMM H Br J Clin Pharmacol. 1987; 24(2):213-20.

PMID: 3620296 PMC: 1387752. DOI: 10.1111/j.1365-2125.1987.tb03164.x.


References
1.
Garteiz D, Walle T . Electron impact fragmentation studies of beta-blocking drugs and their metabolites by GC-mass spectroscopy. J Pharm Sci. 1972; 61(11):1728-31. DOI: 10.1002/jps.2600611106. View

2.
Walle T, Conradi E, Walle U, Gaffney T . O-methylated catechol-like metabolites of propranolol in man. Drug Metab Dispos. 1978; 6(4):481-7. View

3.
Blanke H, Aschbrenner B, Karsch K, Kreuzer H . [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)]. Dtsch Med Wochenschr. 1979; 104(16):587-91. DOI: 10.1055/s-0028-1103950. View

4.
Barlow J, Kellie A . A quantitative method for the chromatographic separation of 17-oxo steroid sulphates from 17-oxo steroid glucuronides with observations on the behaviour of conjugated corticosteroids on the same system. Biochem J. 1959; 71(1):86-91. PMC: 1196753. DOI: 10.1042/bj0710086. View

5.
Hoffmann K, Arfwidsson A, Borg K . The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans. Drug Metab Dispos. 1982; 10(2):173-9. View